JP2021500394A - αタンパク質キナーゼ１を活性化することによって免疫応答をモジュレートするための組成物および方法 - Google Patents

αタンパク質キナーゼ１を活性化することによって免疫応答をモジュレートするための組成物および方法 Download PDF

Info

Publication number
JP2021500394A
JP2021500394A JP2020523748A JP2020523748A JP2021500394A JP 2021500394 A JP2021500394 A JP 2021500394A JP 2020523748 A JP2020523748 A JP 2020523748A JP 2020523748 A JP2020523748 A JP 2020523748A JP 2021500394 A JP2021500394 A JP 2021500394A
Authority
JP
Japan
Prior art keywords
virus
adp
compound
cancer
alpk1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020523748A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021500394A5 (enExample
Inventor
シュ，ティアン
シュ，コン
リュウ，ダンヤン
ファン，ジェチン
パン，イェンファン
リ，トンルエイ・レイモンド
チェン，シャオドン
Original Assignee
シャンハイ・ヤオ・ユアン・バイオテクノロジー・カンパニー・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シャンハイ・ヤオ・ユアン・バイオテクノロジー・カンパニー・リミテッド filed Critical シャンハイ・ヤオ・ユアン・バイオテクノロジー・カンパニー・リミテッド
Publication of JP2021500394A publication Critical patent/JP2021500394A/ja
Publication of JP2021500394A5 publication Critical patent/JP2021500394A5/ja
Priority to JP2023169347A priority Critical patent/JP2023182695A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2020523748A 2017-10-27 2018-10-25 αタンパク質キナーゼ１を活性化することによって免疫応答をモジュレートするための組成物および方法 Pending JP2021500394A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023169347A JP2023182695A (ja) 2017-10-27 2023-09-29 αタンパク質キナーゼ１を活性化することによって免疫応答をモジュレートするための組成物および方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CNPCT/CN2017/107962 2017-10-27
CNPCT/CN2017/107962 2017-10-27
CNPCT/CN2018/083153 2018-04-16
CNPCT/CN2018/083153 2018-04-16
CNPCT/CN2018/100871 2018-08-16
CNPCT/CN2018/100871 2018-08-16
PCT/CN2018/111885 WO2019080898A1 (en) 2017-10-27 2018-10-25 COMPOSITIONS AND METHODS FOR MODULATION OF IMMUNE RESPONSE BY ACTIVATION OF PROTEIN KINASE ALPHA 1

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023169347A Division JP2023182695A (ja) 2017-10-27 2023-09-29 αタンパク質キナーゼ１を活性化することによって免疫応答をモジュレートするための組成物および方法

Publications (2)

Publication Number Publication Date
JP2021500394A true JP2021500394A (ja) 2021-01-07
JP2021500394A5 JP2021500394A5 (enExample) 2021-12-02

Family

ID=66246202

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020523748A Pending JP2021500394A (ja) 2017-10-27 2018-10-25 αタンパク質キナーゼ１を活性化することによって免疫応答をモジュレートするための組成物および方法
JP2023169347A Pending JP2023182695A (ja) 2017-10-27 2023-09-29 αタンパク質キナーゼ１を活性化することによって免疫応答をモジュレートするための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023169347A Pending JP2023182695A (ja) 2017-10-27 2023-09-29 αタンパク質キナーゼ１を活性化することによって免疫応答をモジュレートするための組成物および方法

Country Status (8)

Country Link
US (5) US11186606B2 (enExample)
EP (1) EP3700536A4 (enExample)
JP (2) JP2021500394A (enExample)
KR (1) KR102733555B1 (enExample)
CN (1) CN111565726A (enExample)
AU (1) AU2018355487B2 (enExample)
CA (1) CA3078267C (enExample)
WO (1) WO2019080898A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
WO2015105955A1 (en) 2014-01-08 2015-07-16 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
BR112017028316A2 (en) 2015-06-30 2018-09-04 Sanford-Burnham Medical Research Institute btla fusion protein agonists and uses thereof
KR102733555B1 (ko) 2017-10-27 2024-11-25 상하이 야오 유안 바이오테크놀로지 컴퍼니 리미티드 알파 단백질 키나제 1의 활성화에 의해 면역 반응을 조절하는 조성물 및 방법
WO2019238024A1 (en) 2018-06-14 2019-12-19 National Institute Of Biological Sciences, Beijing Promoting immune responses
EP3958870A1 (en) * 2019-04-26 2022-03-02 Shanghai Yao Yuan Biotechnology Co., Ltd. Derivatives of glycero-manno-heptose adp for use in modulating immune response
WO2021231436A1 (en) * 2020-05-11 2021-11-18 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic methods for treating covid-19 infections
WO2022035917A1 (en) * 2020-08-14 2022-02-17 Merck Sharp & Dohme Corp. Synthesis of fluorinated nucleotides
WO2022127914A1 (en) 2020-12-18 2022-06-23 Pyrotech (Beijing) Biotechnology Co., Ltd. Nucleoside-thiodiphosphate-heptose compounds for treating conditions associated with alpk1 activity
CA3233387A1 (en) 2021-09-30 2023-04-06 Nana Du Nucleoside-diphosphate-heptose compounds for treating conditions associated with alpk1 activity
CN116808216A (zh) * 2022-07-06 2023-09-29 四川大学 Alpk1基因作为脑缺血导致的中枢神经系统疾病的防治靶点的应用
WO2025113626A2 (en) 2023-11-30 2025-06-05 Pyrotech (Beijing) Biotechnology Co., Ltd. Salt forms of alpk1 activators
CN117517657B (zh) * 2024-01-08 2024-04-09 中国农业科学院北京畜牧兽医研究所 Lnx1基因或蛋白在调控禽类先天免疫应答反应中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007119815A1 (ja) * 2006-04-14 2007-10-25 Kyowa Hakko Kirin Co., Ltd. Ｔｏｌｌ様受容体９作動薬

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE7611930U1 (de) 1976-04-15 1977-01-13 Filterwerk Mann & Hummel Gmbh, 7140 Ludwigsburg Vorrichtung zum mischen von koernigem oder pulverfoermigem material mit einem oder mehreren zusatzstoffen
GB2432834A (en) 2004-01-12 2007-06-06 Cytopia Res Pty Ltd Selective Kinase Inhibitors
UA99434C2 (ru) * 2005-12-19 2012-08-27 Аетерна Центаріс Гмбх Применение производных алкилфосфолипидов со сниженной цитотоксичностью
TW200923103A (en) 2007-09-10 2009-06-01 Nat Health Research Institutes ALPK1 gene variants in diagnosis risk of gout
PL2303264T3 (pl) 2008-06-09 2018-08-31 Allergan, Inc. Sposoby leczenia stanów pośredniczonych alfa-adrenergicznie z użyciem pochodnych imidazoliny
CN201735264U (zh) 2010-05-27 2011-02-09 蓝星化工有限责任公司 一种尘降器
CN202590724U (zh) 2010-12-20 2012-12-12 西安磁林电气有限公司 一种加料装置
EP3778896A1 (en) 2011-08-09 2021-02-17 Fred Hutchinson Cancer Research Center Methods and compositions for inhibiting the growth and/or proliferation of myc-driven tumor cells
EP2867237A1 (en) 2012-06-27 2015-05-06 4SC Discovery GmbH Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders
GB201408100D0 (en) 2014-05-07 2014-06-18 Sec Dep For Health The Detection method
CN204182373U (zh) 2014-09-30 2015-03-04 天津博弘化工有限责任公司 流化床下料斗排气装置
EP3204014B1 (en) 2014-10-10 2020-07-01 The Governing Council of the University of Toronto Methods of modulating immune system responses
CN204973750U (zh) 2015-05-26 2016-01-20 柳州钢铁股份有限公司 圆筒混合机刮料器
EP3190062A1 (en) 2016-01-07 2017-07-12 Pont Packaging B.V. A cap construction with a storage space and a container provided therewith as well as a method of using same
CN105536635A (zh) 2016-02-02 2016-05-04 珠海格力智能装备有限公司 一种车用尿素加料装置
CN206366365U (zh) 2016-12-13 2017-08-01 珠海格力智能装备有限公司 吸料装置及具有其的尿素机
CN106582336B (zh) 2016-12-13 2022-09-13 珠海格力智能装备有限公司 吸料装置及具有其的尿素机
KR102733555B1 (ko) 2017-10-27 2024-11-25 상하이 야오 유안 바이오테크놀로지 컴퍼니 리미티드 알파 단백질 키나제 1의 활성화에 의해 면역 반응을 조절하는 조성물 및 방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007119815A1 (ja) * 2006-04-14 2007-10-25 Kyowa Hakko Kirin Co., Ltd. Ｔｏｌｌ様受容体９作動薬

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ＢＩＯＭＥＤＩＣＩＮＥＳ, vol. 2, no. 3, JPN6022050450, 4 August 2014 (2014-08-04), pages 211 - 228, ISSN: 0005247098 *
ＩＮＴＥＲＮＡＴＩＯＮＡＬ ＪＯＵＲＮＡＬ ＯＦ ＯＮＣＯＬＯＧＹ, vol. 53, no. 3, JPN6022050454, 27 June 2018 (2018-06-27), pages 1193 - 1203, ISSN: 0005247100 *
ＪＯＵＲＮＡＬ ＯＦ ＣＬＩＮＩＣＡＬ ＩＮＶＥＳＴＩＧＡＴＩＯＮ ＩＮＳＩＧＨＴ, vol. Ｖｏｌ．２，Ｎｏ．１８，ｅ９３３９７, JPN6022050452, 21 September 2017 (2017-09-21), pages 1 - 18, ISSN: 0005247099 *

Also Published As

Publication number Publication date
KR102733555B1 (ko) 2024-11-25
US20220017560A1 (en) 2022-01-20
US20200283468A1 (en) 2020-09-10
AU2018355487B2 (en) 2023-09-21
EP3700536A1 (en) 2020-09-02
AU2018355487A1 (en) 2020-04-23
JP2023182695A (ja) 2023-12-26
CA3078267C (en) 2024-06-18
US20190367553A1 (en) 2019-12-05
US11773131B2 (en) 2023-10-03
CN111565726A (zh) 2020-08-21
AU2018355487A2 (en) 2020-05-21
US20240124511A1 (en) 2024-04-18
US20210403501A1 (en) 2021-12-30
WO2019080898A1 (en) 2019-05-02
US11840551B2 (en) 2023-12-12
US11149051B2 (en) 2021-10-19
US11186606B2 (en) 2021-11-30
KR20200090154A (ko) 2020-07-28
EP3700536A4 (en) 2021-11-17
CA3078267A1 (en) 2019-05-02

Similar Documents

Publication Publication Date Title
US11773131B2 (en) Compositions and methods of modulating the immune response by activating alpha protein kinase 1
JP7483975B2 (ja) 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート
KR102656571B1 (ko) 아르기나아제 억제제
CN105008381B (zh) 包含具有确定立体化学的环嘌呤二核苷酸的组合物及其制备和使用方法
JP2590248B2 (ja) 抗ウイルス・抗腫瘍・抗転移・免疫系増強ヌクレオシド類およびヌクレオチド類
CA2626997C (en) Analogs of alpha galactosylceramide and uses thereof
US20220177510A1 (en) Derivatives of gylcero-manno-heptose adp for use in modulating immune response
US20220213135A1 (en) Derivatives of glycero-manno-heptose phosphate and their use in modulating an immune response
RU2809547C2 (ru) Новое производное циклического динуклеотида и его конъюгат антитело-лекарственное средство
JP2003204793A (ja) ウイルス性疾患の予防または治療剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211022

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211022

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230227

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20231002

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231124

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251023